OneDigital Investment Advisors LLC Increases Stock Position in MDxHealth SA (NASDAQ:MDXH)

OneDigital Investment Advisors LLC increased its holdings in MDxHealth SA (NASDAQ:MDXH) by 15.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,726 shares of the company’s stock after acquiring an additional 7,656 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in MDxHealth were worth $120,000 at the end of the most recent quarter.

Separately, Perkins Capital Management Inc. raised its stake in shares of MDxHealth by 70.7% during the third quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock worth $1,555,000 after purchasing an additional 309,500 shares during the last quarter.

MDxHealth Price Performance

MDxHealth stock opened at $1.88 on Friday. The stock’s 50 day moving average price is $2.06 and its 200 day moving average price is $2.52. MDxHealth SA has a 1-year low of $1.55 and a 1-year high of $4.64. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54.

MDxHealth (NASDAQ:MDXH) last issued its earnings results on Wednesday, August 21st. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.05). MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. The company had revenue of $22.16 million for the quarter, compared to analysts’ expectations of $20.66 million. Equities analysts anticipate that MDxHealth SA will post -1.15 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MDXH shares. Lake Street Capital began coverage on shares of MDxHealth in a research note on Thursday, October 31st. They issued a “buy” rating and a $7.00 price objective on the stock. Piper Sandler dropped their price target on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.